NCT02500914 (Clinical Trial/ SC-002)

Study Title
SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma (NCT02500914)

Trial Description
This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy.

The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC and LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002

This trial is sponsored by Stemcentrx®

Study Data

  • Condition:
    • Small Cell Lung Cancer
    • Large Cell Neuroendocrine Carcinoma
  • Interventions:
    • Drugs used in this trial
      • SC-002
  • Phase: I
  • Estimated Enrollment: 102
  • Start: June 2015
  • Completion: December 2016
  • Last updated: April 2016
  • Last verified: April 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: April 16, 2016
Information based on (NIH/NCI) and other sources.